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What’s already known about this topic?  
• Squamous cell carcinoma (SCC) commonly arises in actinically damaged skin. 
• Intraepidermal carcinoma (IEC) is a precursor of SCC that usually develops on sun 
exposed skin.  
• Actinic keratoses (AKs) are associated with an increased risk of SCC. 
• Actinic field change represents keratinocytes with UV-specific pre-cancerous genetic 
mutations. 
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What does this study add?  
• Certain features of actinic damage on pre-defined areas of skin on the head, neck and 
upper limbs can predict short-medium term SCC or IEC risk. 
• The presence of AK that affects greater than 1cm2 skin (AK patch) on a pre-defined 
site significantly increases risk of SCC or IEC within 18 months. 
• The number of AKs and the percentage of area affected by AKs are also associated 
with an increased risk of SCC or IEC. 
 
ABSTRACT  
Background: Squamous cell carcinoma (SCC) and intraepidermal carcinoma (IEC) 
commonly arise in actinically damaged skin.  
Objective: To identify clinical features of actinic change that correlate with an increased risk 
of SCC or IEC in the short-medium term as guidance for prioritising field treatment. 
Methods: In a nested case-control study, cases were renal transplant recipients (RTRs) who 
developed an incident SCC or IEC within 18 months following baseline examination and 
photography. Controls without SCC/IEC were matched to cases on age, sex and duration of 
immunosuppression. Pre-defined skin sites on head, neck and upper limbs were examined 
using baseline photographs to objectively assess the following features of actinic damage: 
presence of actinic keratosis (AK) patch (defined as AK >1cm2), number of AK patches, 
number of AKs and area affected by AK. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were calculated using McNemar’s test to identify differences in SCC/IEC risk 
combined and SCC risk alone between case and control skin sites.  
Results: 39 cases were matched to 39 controls. Significant associations with the presence of 
an AK patch, number of AK patches, number of AKs and area affected by AKs were 
identified. The presence of an AK patch conferred an 18-fold increased risk of SCC (OR 
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18.00, 95% CI 2.84-750) and a 7-fold increased risk of SCC/IEC combined (OR 6.6, 95% CI 
2.56-21.66).  
Conclusion: AK patches are predictive of SCC/IEC development within 18 months. This can 
be used to guide site selection for field treatment in patients with widespread actinic damage.  
 
INTRODUCTION 
Cutaneous squamous cell carcinoma (SCC) is a malignant tumour of epidermal 
keratinocytes that usually arises on body sites with high sun exposure. 1,2  Ultraviolet (UV) 
radiation is recognised as a principal cause with epidemiological studies showing a 
significant association with occupational sun exposure and cumulative sun exposure. 3,4  
Intraepidermal carcinoma (IEC) also arises on sun-exposed sites and is often associated with 
SCC. 5-7  Mutations in the p53 oncogene are commonly detected in IEC and SCC, suggesting 
that dysregulation of p53 pathways is a key event in SCC carcinogenesis. 8  Furthermore, UV 
radiation has been identified as a cause of p53 mutations in keratinocytes. 9  
Actinic keratoses (AKs) are intraepithelial dysplastic keratinocytic lesions which are 
diagnosed clinically as scaly erythematous papules or plaques.  They frequently arise on 
heavily sun-exposed sites as a recognised consequence of chronic UV damage. 10,11 AKs are a 
strong risk factor for SCC, both in the general population and in immunosuppressed 
transplant recipients. 12,13 A recent study has shown that the presence of large confluent AKs 
(>1cm2) is an additional risk factor for SCC in transplant recipients. 14  
The evidence, therefore, corroborates the view that SCC and IEC primarily occur in 
actinically damaged skin that has undergone genetic mutation, supporting the notion of ‘field 
change’ in the genesis of cutaneous SCC.15,16 Specifically, field change has been 
histopathologically defined as an area consisting of abnormal epithelial cells, which do not 
show invasive growth or metastatic behaviour.17 These areas likely represent the first stages 
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of carcinogenesis and although it is recommended to treat actinic field change, there is 
insufficient evidence to establish a working clinical definition of what constitutes field 
change.18-21 Developing such a definition is clinically important to enable the identification 
and treatment of areas of skin that carry the greatest risk of malignancy, particularly in 
patients with widespread actinic damage.  
Therefore the aim of this study was to identify precise clinical parameters for actinic 
damage which can be used to predict the short- to medium-term risk of SCC or IEC on pre-
defined areas of sun-exposed skin and to facilitate selection of skin sites with priority for 
field treatment.  
 
METHODS 
Study design 
A nested, anatomic site-specific, case-control study was conducted among 
participants of the Skin Tumours in Allograft Recipients (STAR) cohort. STAR is a 
prospective study whose primary aim is to assess the skin cancer burden and associated 
factors in organ transplant recipients (OTRs) in subtropical Queensland. White-skinned 
Caucasian OTRs were eligible for inclusion if they were aged 18 years and over, at least one 
year post-transplant with stable immunosuppression and had a history of skin cancer or AK, 
or if no such history, were aged 40 years or older or had received at least 10 years of 
immunosuppressive therapy.  OTRs were excluded if there was a history of recent topical 
field treatment (< 6 months) or if they were receiving oral retinoid therapy (unless on a stable 
dose for > 6 months).  The study received approval from relevant institutional ethics 
committees and participants provided written informed consent.  
All participants received a detailed baseline skin examination by a trained physician. 
Participants were subsequently examined at 12-monthly intervals at study clinics, with three-
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monthly telephone interviews to ensure all interim skin cancers between annual study skin 
examinations were identified. All skin tumours suspected of malignancy at study clinics and 
all self-reported skin cancers were histopathologically confirmed.  
Cases were study RTRs who developed an incident SCC or IEC on the face, forearms 
or hands within 18 months of baseline skin examination. Controls were defined as RTRs who 
did not develop SCC or IEC on the pre-defined study subsites face, forearms or hands within 
18 months of the baseline skin examination (given this was a priori a site-specific study, 
controls may have developed SCC/IEC on non-study sites without violating the study 
protocol).  
Cases and controls were matched 1:1 on sex, age (± 5 years) and time since first 
transplantation (± 5 years), the latter representing duration of immunosuppression. In 
addition, cases were matched to controls on the basis of pre-defined skin sites, namely seven 
facial sites and four upper limb sites, including exact matching on laterality. Pre-defined skin 
sites were chosen for the present study of clinical features of actinic damage according to 
ease and feasibility of treating the entire area. In total, 11 skin sites that were potentially 
treatable topically were examined: left and right upper face (demarcated by the normal 
hairline, the upper eyebrow edge, the midline of the face and a line from the lateral canthus to 
the tragus of the ear), left and right lower face (demarcated by a line from the lateral canthus 
to the ear, the lower eyebrow edge, the midline of the face, outermost edge of nasal sidewall 
and the edge of the jaw), nose, left and right ear, left and right dorsal forearm (demarcated by 
the wrist and elbow crease) and left and right dorsal hand (Fig. 1).   
 If multiple skin sites were examined per participant, these were each matched to an 
identical skin site in the control participant. In instances where SCC and IEC had developed 
on the same skin site, only one outcome of either SCC alone or SCC/IEC combined was 
analysed.   
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Data collection 
Standardised high quality digital photographs were taken of the face, forearms and 
hands of RTRs at baseline using a Canon DS126271 digital camera with Macro Lens EF-S 
60mm 1:2:8 USM (Tokyo, Japan), photo-studio flash lighting, a soft-box and white screen.  
The baseline digital photographs of identified case and control skin sites were 
subsequently examined by a dermatology-trained physician to identify the following features 
of actinic damage: the presence of an AK patch (defined as an AK greater than 1cm2), the 
number of AK patches and the number of AKs. Additionally the percentages of the defined 
areas affected by AK, erythema and pigment change (hypo- and hyperpigmentation) were 
assessed and recorded as 0%, 1-25%, >25-50%, >50%-75% or >75%. All assessments of 
digital photographs of participants’ skin were conducted blinded to the case/control status of 
the participants. AK was identified on photographs as a scaly erythematous papule or 
plaque.16 
 
Statistical analysis 
Baseline characteristics of cases and controls were summarised and differences 
between matched pairs tested for significance using paired t-test.  Potential explanatory 
variables were dichotomised and McNemar’s test was applied to identify features of actinic 
damage significantly associated with the two outcomes of developing a) either SCC or IEC 
and b) SCC alone. Odds ratios and 95% confidence intervals (CIs) were calculated as the 
measure of association. Kendall’s tau-b test was used to assess the correlation between AK 
counts on photographs versus clinical examination in a random selection of 30 skin sites. A P 
value of 0.05 or less was considered significant. All analyses were performed using SPSS v21 
(Armonk, NY: IBM Corp). 
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RESULTS 
Of 59 cases and 95 controls that fulfilled inclusion criteria, 39 cases with complete 
high quality photographs were successfully matched to 39 controls.  Of the 39 matched pairs, 
26 were male. Ages ranged from 32 to 75 years and mean age of cases (58 ± 9 years) and 
controls (57 ± 9 years) were very similar.  Duration of immunosuppression ranged from 1 to 
25 years with mean 9 (± 7) years for cases and controls.  The overall differences between 
matched pairs were -0.9 years for age and -0.3 years for duration of immunosuppression.  
69 matched skin sites were evaluated in total, as 14 case participants developed SCC 
or IEC on multiple skin sites and six skin sites developed both SCC and IEC and therefore 
these were analysed as one for the outcome of SCC/IEC combined (Table 1). Of the 69 
matched skin sites, a new SCC developed on 27 case skin sites and an IEC occurred on 48 
overlapping case skin sites in the 18 months follow-up period (Table 1; Fig. 1).  Twenty of 
the 27 SCCs showed moderate differentiation, three were poorly differentiated and four were 
well differentiated; only one SCC was greater than 2cm in diameter.  The left lower face was 
the skin site with the highest number of new SCC and IEC lesions in the study period.  
 
SCC/IEC combined 
An AK patch was present on 58% of case skin sites at baseline that developed either 
SCC or IEC in the following 18 months but on only 17% of control skin sites at baseline 
(Table 2). The number of AK patches ranged from 0-6 in control skin sites (median 0) and 0-
13 in case sites (median 1). The presence of an AK patch significantly increased the risk of 
either SCC or IEC by more than 6-fold (OR 6.6, 95% CI 2.56-21.66). Skin sites with three or 
more AK patches also had a significantly increased risk of either SCC or IEC when compared 
with sites with less than three AK patches (OR 5.68, 95% CI 1.64-30.18).  The total number 
of AKs per site ranged from 0-49 in all participants and only 16% of case skin sites had 0 
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AKs compared with 45% of control skin sites. Furthermore, the majority of case skin sites 
had three or more AKs (64%) whilst only 22% of control skin sites had this feature, 
corresponding to a more than 4-fold increase in risk of either SCC or IEC (OR 4.63, 95% CI 
2.12-11.45).  23% of case skin sites had AKs involving 25% or more of the area compared 
with only 4% of control skin sites and this was statistically significant (OR 5.33, 95% CI, 
1.53-28.56).  There was no significant difference in area affected by erythema or 
pigmentation change between case and control sites (P value 0.15 and 0.58, respectively). 
 
SCC alone 
With regards to the SCC only outcome, variation between case and control sites was 
more pronounced. The vast majority of case skin sites with incident SCC (78%) had an AK 
patch present at baseline, compared with only 15% of control skin sites and risk of SCC was 
increased by almost 20-fold (OR 18.00, 95% CI 2.84-750).  There were three or more AK 
patches on 10 case skin sites (37%) versus only one control skin site (4%). There was also a 
notable difference in the number of AKs with the majority of case skin sites (82%) having 
three or more AKs compared with only 15% of control skin sites.  No control skin sites had 
>25% of the area involving AKs, whereas this was true in 41% of skin sites that later 
developed SCC. Further analysis could not be performed for the variables ‘number of AK 
patches’, ‘number of AKs’ and ‘percentage of area involving AK’ due to lack of sufficient 
discordant matched pairs. There was no significant difference in area affected by erythema or 
pigment change between case and control sites (P > 0.05). 
 
Consistency of photographic and clinical assessment of AKs 
Consistency of assessing baseline AK counts using digital photographs compared 
with clinical examination (as recorded by examining physicians at baseline on standard body-
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charts) was evaluated in a random selection of 30 skin sites examined. Given that AK counts 
vary considerably in clinical examinations between physicians 22,23 and that tactile 
information is absent in photographic assessment, a tolerance of ± 1 AK was set for the 
comparison between photographs and clinical examination. Using this method, AK counts 
from photographs were consistent with AK counts at baseline clinical examination for 25 of 
the 30 (83%) randomly evaluated pre-defined sites on the head and neck (Kendall’s tau-b 
correlation coefficient = 0.78, P <0.001). 
 
DISCUSSION 
It is widely accepted that actinic damage is a risk factor for SCC in both the general 
and immunosuppressed populations. 24-26  However, because AKs are so prevalent in exposed 
skin with severe actinic damage, identifying confined anatomic skin sites at high risk of 
developing SCC or IEC is essential to enable targeted treatment. Our study is novel in its 
examination of pre-defined skin sites because of the practicability for targeted treatment and 
in its establishing high risk of either SCC or IEC in the short-medium term (18 months). 
Furthermore, this is the first study to explore the relevance of an AK patch in localised, pre-
defined areas of skin. 
We showed that a defined skin site with an AK greater than 1cm2 (AK patch) is 
approximately seven times more likely to develop either SCC or IEC than sites without this 
feature. Furthermore, skin sites with an AK patch present had an almost 20-fold increased 
risk of SCC, when compared with skin sites without this feature (95% CI 2.84-750) (the wide 
confidence interval reflecting the small numbers of discordant pairs in the assessment of SCC 
risk).   The number of AK patches was also associated with an increased risk with sites 
having three or more AK patches being six times more likely to develop either SCC or IEC 
within an 18 month period than those with less than three AK patches. This may be an 
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underestimation, however, as only 22 skin sites had three or more AK patches present. Skin 
sites with three or more AKs or AKs covering 25% or more of the total area of the field had a 
five-fold increased risk of either SCC or IEC compared with sites with less than 25% area 
affected.  
Risk estimates for SCC alone could not be calculated because of zero cell numbers in 
the discordant combination of low for cases and high for controls for the variables number of 
AK patches, number of AKs and percentage area involving AK. This discordance in itself 
highlights the significant disparity between actinic damage in case and control sites and 
illustrates the dramatic effect these factors have on SCC risk. The percentage of area affected 
by erythema and pigmentation change did not vary significantly between case and control 
sites for either outcome of SCC/IEC combined or SCC alone.  
Previous studies have quantified the risk of AK progression to SCC with the hope of 
directing management towards either active treatment or a ‘watch and wait’ approach. The 
risk estimations for progression to SCC have varied between 0-0.53% per year, leaving 
clinicians with differing opinions on the cost-benefit result of treating AKs. 13,27 Our study 
therefore provides important evidence required to guide the management of actinically 
damaged skin and hence to create a new practical clinical working definition of actinic field 
change by exploring the concept of AK patch, which could guide clinicians to a staggered 
approach for field-directed treatment.  
We recognise that this study is limited by the small numbers of cases, particularly 
SCC, where a larger sample would have improved risk estimation.  Our study was 
underpowered and a larger study may be required to confirm that AK patches are 
independently predictive of SCC/IEC development. Additionally, although we examined 11 
pre-defined skin sites, the various facial and upper limb skin sites were not of equal size. 
Furthermore, using two or more assessors to extract the photography data would have 
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enabled a comparison and assessment of inter-observer reliability.  High-quality digital 
photographs (as opposed to advanced imaging techniques) were used as reasonable 
surrogates for clinical examination, which in practice does not allow painstaking assessment 
of details of actinic damage such as surface area affected. There was high positive correlation 
between AK counts using photography and on clinical examination, thereby supporting the 
consistency of our method of using photography for the assessment of actinic damage. 
Moreover, the blind assessment of the photographs ensured that any significant variations in 
results between case and control sites cannot be explained on the basis of bias or technique 
alone.  Therefore, although photography was used, we believe the results of this study can be 
extrapolated to the clinical setting with significant features guiding site selection and 
treatment. Additionally despite only examining RTRs, studies have shown that keratinocyte 
cancers in RTRs and the general population share very similar risk factors and likely a similar 
aetiology. 1,25  We therefore believe that the results of this study are generalizable to 
immunocompetent patients, although skin cancers in the latter are likely to develop in the 
longer term rather than within an 18 month period as observed here in RTRs.    
In conclusion, this study has identified clinical risk factors on pre-defined skin sites 
that can be used as predictors for malignancy in the short to medium term. Field-directed 
treatment such as the use of topical agents, photodynamic or laser therapy, aimed at high-risk 
sites with features such as the presence of an AK patch can be employed, particularly in 
patients with widespread actinic damage to reduce future SCC/IEC risk. Further research 
directed at site-specific analysis is required to better understand site-specific risk factors and 
prioritise field-directed treatment in individuals with a high degree of UV damage.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
1 English DR, Armstrong BK, Kricker A et al. Demographic characteristics, 
pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a 
case-control study. International journal of cancer. Journal international du cancer 
1998; 76: 628-34. 
2 Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal 
transplantation in The Netherlands. Transplantation 1990; 49: 506-9. 
3 Schmitt J, Seidler A, Diepgen TL et al. Occupational ultraviolet light exposure 
increases the risk for the development of cutaneous squamous cell carcinoma: a 
systematic review and meta-analysis. The British journal of dermatology 2011; 164: 
291-307. 
4 Rosso S, Zanetti R, Martinez C et al. The multicentre south European study 'Helios'. 
II: Different sun exposure patterns in the aetiology of basal cell and squamous cell 
carcinomas of the skin. British journal of cancer 1996; 73: 1447-54. 
5 Kao GF. Carcinoma arising in Bowen's disease. Archives of dermatology 1986; 122: 
1124-6. 
6 Jaeger AB, Gramkow A, Hjalgrim H et al. Bowen disease and risk of subsequent 
malignant neoplasms: a population-based cohort study of 1147 patients. Archives of 
dermatology 1999; 135: 790-3. 
7 Hansen JP, Drake AL, Walling HW. Bowen's Disease: a four-year retrospective 
review of epidemiology and treatment at a university center. Dermatologic surgery : 
official publication for American Society for Dermatologic Surgery [et al.] 2008; 34: 
878-83. 
8 Campbell C, Quinn AG, Ro YS et al. p53 mutations are common and early events that 
precede tumor invasion in squamous cell neoplasia of the skin. The Journal of 
investigative dermatology 1993; 100: 746-8. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
9 Brash DE, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UV-
induced p53 mutations in squamous cell carcinoma. Proceedings of the National 
Academy of Sciences of the United States of America 1991; 88: 10124-8. 
10 Traianou A, Ulrich M, Apalla Z et al. Risk factors for actinic keratosis in eight 
European centres: a case-control study. The British journal of dermatology 2012; 167 
Suppl 2: 36-42. 
11 Memon AA, Tomenson JA, Bothwell J et al. Prevalence of solar damage and actinic 
keratosis in a Merseyside population. The British journal of dermatology 2000; 142: 
1154-9. 
12 Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with 
nonmelanoma skin cancer in renal transplant recipients. American journal of kidney 
diseases : the official journal of the National Kidney Foundation 2000; 36: 167-76. 
13 Werner RN, Sammain A, Erdmann R et al. The natural history of actinic keratosis: a 
systematic review. The British journal of dermatology 2013; 169: 502-18. 
14 Wallingford SC, Russell SA, Vail A et al. Actinic Keratoses, Actinic Field Change 
and Associations with Squamous Cell Carcinoma in Renal Transplant Recipients in 
Manchester, UK. Acta dermato-venereologica 2015. 
15 Carlson JA, Scott D, Wharton J et al. Incidental histopathologic patterns: possible 
evidence of 'field cancerization' surrounding skin tumors. The American Journal of 
dermatopathology 2001; 23: 494-6. 
16 Soyer HP, Rigel D, Wurm EMT. Actinic Keratosis, Basal Cell Carcinoma and 
Squamous Cell Carcinoma. In: Dermatology (Basel, Switzerland) (Bolognia JL JJ, 
Schaffer JV, ed): Elsevier. 2012; 1773–93. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
17 Braakhuis BJ, Tabor MP, Kummer JA et al. A genetic explanation of Slaughter's 
concept of field cancerization: evidence and clinical implications. Cancer research 
2003; 63: 1727-30. 
18 Dreno B, Amici JM, Basset-Seguin N et al. Management of actinic keratosis: a 
practical report and treatment algorithm from AKTeam expert clinicians. Journal of 
the European Academy of Dermatology and Venereology : JEADV 2014; 28: 1141-9. 
19 Vatve M, Ortonne JP, Birch-Machin MA et al. Management of field change in actinic 
keratosis. The British journal of dermatology 2007; 157 Suppl 2: 21-4. 
20 Hofbauer G, Anliker M, Boehncke WH et al. Swiss clinical practice guidelines on 
field cancerization of the skin. Swiss medical weekly 2014; 144: w14026. 
21 Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. Journal 
of the European Academy of Dermatology and Venereology : JEADV 2015; 29 Suppl 
1: 3-8. 
22 Weinstock MA, Bingham SF, Cole GW et al. Reliability of counting actinic keratoses 
before and after brief consensus discussion: the VA topical tretinoin chemoprevention 
(VATTC) trial. Archives of dermatology 2001; 137: 1055-8. 
23 Sinnya S, O'Rourke P, Ballard E et al. Counting Actinic Keratosis - Is Photographic 
Assessment a Reliable Alternative to Physical Examination in Clinical Trials? Acta 
dermato-venereologica 2015; 95: 604-5. 
24 Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk 
Australian population. International journal of cancer. Journal international du 
cancer 1990; 46: 356-61. 
25 Ramsay HM, Fryer AA, Hawley CM et al. Factors associated with nonmelanoma skin 
cancer following renal transplantation in Queensland, Australia. Journal of the 
American Academy of Dermatology 2003; 49: 397-406. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
26 Savoia P, Stroppiana E, Cavaliere G et al. Skin cancers and other cutaneous diseases 
in renal transplant recipients: a single Italian center observational study. European 
journal of dermatology : EJD 2011; 21: 242-7. 
27 de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic 
keratoses. The British journal of dermatology 2007; 156: 222-30. 
 
Table 1. Location of incident squamous cell carcinoma (SCC), intraepidermal carcinoma 
(IEC) and numbers of actinic keratoses (AKs) and AK patches on case skin sites 
Skin site Number 
of cases 
with 
SCCs 
n (%) 
Number 
of cases 
with IECs 
n (%) 
Total 
IEC/SCC
n (%) 
Total 
number 
of AKs 
n (%) 
Total 
number 
of AK 
patches  
n ( %) 
Left 
upper 
face 
2 (7) 4 (8) 6 (8) 26 (8) 11 (9) 
Right 
upper 
face 
4 (15) 7 (15) 11 (15) 41 (12) 21 (17) 
Left ear 3 (11) 2 (4) 5 (7) 7 (2) 4 (3) 
Right ear 0 (0) 2 (4) 2 (3) 6 (2) 3 (2) 
Left 
lower 
face 
4 (15) 10 (21) 14 (19) 50 (15) 20 (17) 
Right 
lower 
face 
2 (7) 3 (6) 5 (7) 29 (8) 9 (7) 
Left 
forearm 
3 (11) 5 (10) 8 (11) 36 (11) 7 (6) 
Right 
forearm 
2 (7) 4 (8) 6 (8) 70 (20) 14 (12) 
Left hand 2 (7) 4 (8) 6 (8) 23 (7) 3 (2) 
Right 
hand 
4 (15) 4 (8) 8 (11) 47 (14) 25 (21) 
Nose 1 (4) 3 (6) 4 (5) 5 (1) 4 (3) 
Total 27 (100) 48 (100) 75 (100)* 340 
(100) 
121 (100) 
 
* Only 69 case skin sites examined in total, as 6 sites which developed both SCC and IEC were 
analysed as one for the outcome of either SCC or IEC. 
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Table 2. Summary of differences between case and control skin sites with calculated odds 
ratios (ORs) and 95% confidence intervals (CI) 
 SCC/IEC combined SCC alone 
Variable Case 
skin 
sites 
n 
(%) 
Control 
skin 
sites 
n (%) 
Odds 
ratio 
(95% 
CI) 
P 
value 
Case 
skin 
sites 
n 
(%) 
Control 
skin 
sites 
n (%) 
Odds 
ratio 
(95% 
CI) 
P 
value 
Presence of 
actinic 
keratosis 
patch 
No 
Yes 
29 
(42) 
40 
(58) 
57 (83) 
12 (17) 
6.60 
(2.56- 
21.66) 
<0.001 6 
(22) 
21 
(78) 
23 (85) 
4 (15) 
18.00 
(2.84-
750) 
<0.001 
No. actinic 
keratosis 
patches 
0-2 
3+ 
51 
(74) 
18 
(26) 
65 (94) 
4 (6) 
5.68 
(1.64-
30.18) 
0.004 17 
(63) 
10 
(37) 
26 (96) 
1 (4) 
* <0.001 
No. actinic 
keratosis 
0 -2 
3+ 
25 
(36) 
44 
(64) 
54 (78) 
15 (22) 
4.63 
(2.12-
11.45) 
<0.001 5 
(18) 
22 
(82) 
23 (85) 
4 (15) 
 
* 
<0.001 
Percentage of 
area involving 
actinic 
keratosis 
<25%
>25% 
53 
(77) 
16 
(23) 
66 (96) 
3 (4) 
5.33 
(1.53-
28.56) 
0.006 16 
(59) 
11 
(41) 
27 (100) 
0 (0) 
 
* 
 
0.014 
Percentage of 
area involving 
erythema 
<25%
>25% 
49 
(71) 
20 
(29) 
57 (83) 
12 (17) 
2.00 
(0.81-
5.40) 
0.15 19 
(70) 
8 
(30) 
20 (74) 
7 (26) 
1.17 
(0.34-
4.2) 
0.88 
Percentage of 
area involving 
pigmentation 
change 
<25%
>25% 
54 
(78) 
15 
(22) 
51 (74) 
18 (26) 
1.6 
(0.46-
6.22) 
0.58 20 
(74) 
7 
(26) 
21 (78) 
6 (22) 
1.50 
(0.17-
17.96) 
0.65 
 
* Incalculable due to lack of discordance within matched pairs. 
 
 
 
 
Figure 1. Demarcation of selected facial and upper limb skin sites 
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